secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2026-08-11T12:30:17+00:00
Accession:  0001193125-26-343525
Event type: litigation
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx settles DOJOLVI patent litigation; Esjay generic entry set for 2033
------------------------------------------------------------------------------

- Settlement with Esjay resolves ANDA patent suit over DOJOLVI (triheptanoin) in NJ district court.
- Esjay gets non-exclusive royalty-free license to market generic DOJOLVI starting Jan 1, 2033, or Jul 1, 2033 if pediatric exclusivity granted.
- Other DOJOLVI ANDA patent suits against other filers remain pending in same court.
- Settlement to be submitted to FTC and DOJ as required by law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526343525/0001193125-26-343525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526343525/rare-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer